Psychedelic drug MDMA could be ‘a new avenue of treatment’ as FDA begins its first-ever review

The independent panel, which is advising the FDA, will discuss MDMA-based therapy for PTSD patients.

A panel of advisers to the U.S. Food and Drug Administration will meet on Tuesday to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder (PTSD).